NMC
PRLD icon

Nine Masts Capital’s Prelude Therapeutics PRLD Stock Holding History

Nine Masts Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40K Buy
+11,699
New +$30.7K 0.01% 180

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Nine Masts Capital's PRLD Position: Q1 2026 in Review

Nine Masts Capital opened a new position in Prelude Therapeutics (PRLD) in Q1 2026: 11,699 shares worth $40K. The stake represents 0.01% of the portfolio and ranks #180 among its holdings.

55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Nine Masts Capital held 11,699 shares of Prelude Therapeutics worth $40K as of Q1 2026.
  • Prelude Therapeutics was a new Nine Masts Capital position in Q1 2026.
  • Prelude Therapeutics made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #180 holding.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.